The Public Technology Platform established in 2022 is affiliated to Medical Research Center of Zhejiang University International Institutes of Medicine, and composed of Public Experiment Platform, Public Instrument Platform and Biobank. The purpose the Public Technology Platform is to provide high-quality, efficient and professional technical services for Zhejiang University International Institutes of Medicine, Fourth Affiliated Hospital of Zhejiang University School of Medicine and Zhejiang University International School of Medicine. The services include instrument training, experimental operation, biological samples management, etc.

The Public Instrument Platform is located on the 18th floor with 1700 square meters in Zhejiang University International Institutes of Medicine, and including Imaging Platform, Protein Analysis Platform, Physical and Chemical Analysis Platform, Flow Cytometry Platform, Biochemical Platform, Histomorphological Platform, etc. The instruments valued around 35 million yuan include BD Fortessa Flow Cytometer, BD FACSAria™ III Cell Sorter, Spinning-disk Confocal Microscope, High Content Screening System, Seahorse XFe96, HPLC and Cytiva(GE) AKTATM pure, etc. There are professional experimental technology instructors for guidance and efficient online reservation sharing information system to meet the needs of all researcher and students.

The Public Experiment Platform is located on the 14th floor with 1700 square meters of laboratory area, and equipped with more than 50 experimental instruments. It is an open laboratory for the scientific researchers to conduct cell and molecular biological experiments.

The Biobank established in 2018 is located on the 1st basement floor of Fourth Affiliated Hospital of Zhejiang University School of Medicine. Currently, the maximum sample storage capacity of Biobank is 150,000 and it is equipped with - 80 ℃ ultra-low temperature refrigerators, liquid nitrogen tanks and liquid nitrogen transfer boxes, etc. The Biobank will be expanded in space and instruments and the information system will be upgraded to meet the needs of biosafety requirements and sample storage for hospital researchers. We will strive to obtain the approval of human genetic preservation and CNAS-AL21 biological sample bank quality and capacity accreditation in 2023.